#MarketExclusivity dilemma for #Orphandrugs in Europe

In Uncategorized by Matt Turner

orphan drug market exclusivity, rare disease treatments, remco de vrueh, dutch steering committee on orphan drugs, In the interest of patients suffering globally from rare diseases, there must be an understanding of the consequences of the market exclusivity incentive of the European Orphan Drug Act.

Does market exclusivity in the orphan drug arena create a market monopoly for the first approved treatment? Or is follow on orphan drug development simply a matter of time or market size?

Download this whitepaper to uncover the findings to this discussion and gain an insight into the nature of the debates that will be going on over 3 days at the World Orphan Drug Congress 2011 in Geneva on the 29th November – 1st December. 

One of the authors of this publication, Remco de Vrueh of the Dutch Steering Committee on Orphan Drugs will be speaking at the congress and will share his expertise on how to translate rare disease research into an orphan drug development programme.

Download the brochure to review the full agenda

Register before 21st October 2011 to receive the maximum discount and take advantage of our early bird offer at http://www.terrapinn.com/2011/world-orphan-drug-congress/

We look forward to welcoming you to Geneva in November